

In silico Synthetic Biology: from research to the market

Isabel Rocha











Industrial Biotechnology


Feedstock Bio-process Production of chemicals Renewable resources / Waste streams Industrial process

The Synthetic Biology Cycle



Developments at the University (since 2004)






Starting a company

based on *in silico*Synthetic Biology

biolteams

bio-innovation teams




- Focusing on services or proprietary microbial strain development?
- Is there market for services?
- Who cares about the technology?
- Some answers provided by a market research performed by some of the founders within MIT-Portugal






Main Milestones





The **GPS** analogy...








Models of Microbes

Re-annotation of metabolic functions Homology search **Transporters** Compartment association Model validation Data integration Integration with available models Heterologous pathways database

- ✓ Model construction
- Pathway screening

Artifical intelligence based **Algorithms**




✓ Rational design supported by prediction of the strategy feasibility

- ✓ Cell simulation
- ✓ Product optimization





Working with leading chemical, materials and synthetic biology companies




SYNTHETIC BIOLOGY

Butanol – novel precursor for an old product

n-Butanol is a chemical currently obtained from petrochemical processes with many applications in industry. It is also one of the fuels of the future









SYNTHETIC BIOLOGY

Predicting the effect of adding new reactions to the network







Ferreira et al (2018) Patent pending



Some Lessons Learnt:

- The team and persistence is more important than having a clear idea for a company since the beginning
- Many investors/advisors are biased towards product-oriented business models
- A dedicated and committed team was essential for achieving our goals
- Funding is always essential, but the amounts and sources vary a lot in our case not much was needeed for launching the company.
- Continuous development of the technology was essential for upcoming stages. This was possible mainly through reinvestment of profits.
- A careful allocation of resources is essential

My personal pathway:

- PhD in 2003/Post-Doc 2004
- First company (Biotempo) in 2002 Bioprocess Development
- UMInho Faculty 2004 2017
- MIT short-term visit in 2007
- Second Company (SilicoLife) in 2011
- Pro-Rector at NOVA since 2017
- Third company soon (?)



A multidisciplinary team

which includes expertise in the Life Sciences, Bioengineering, Computer Science and Bioinformatics.



Main Founders

Simão Soares

MSc Bioinformatics
BSc Informatics Engineering
Board member P-Bio

Miguel Rocha

PhD Computer Science UMinho Faculty Bioinformatics expert

Isabel Rocha

PhD Chemical Engineering UMinho Faculty Founder Biotempo

Paulo Vilaça

MSc Bioinformatics BSc Informatics Engineering

Bruno Sommer Ferreira

PhD Biotechnology Biotrend CEO